ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.626,45
1,05%
S&P 500
6.032,38
0,56%
Dow Jones
44.910,65
0,42%
Euro vs US Dollar
1,0579
-0,01%
Bitcoin
96.670,45
-0,84%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Virios Therapeutics Inc (VIRI)

  7. Virios Therapeutics Inc (VIRI) News

VIRI

Virios Therapeutics (VIRI)

Virios Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:VIRI
DatumZeitQuelleÜberschriftSymbolFirma
21/11/202415h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
08/11/202414h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIRIVirios Therapeutics Inc
07/11/202413h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
30/10/202414h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
17/10/202422h30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VIRIVirios Therapeutics Inc
17/10/202422h29Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VIRIVirios Therapeutics Inc
15/10/202422h19Edgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:VIRIVirios Therapeutics Inc
07/10/202414h06Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:VIRIVirios Therapeutics Inc
07/10/202414h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
07/10/202413h05GlobeNewswire Inc.Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)NASDAQ:VIRIVirios Therapeutics Inc
09/08/202416h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIRIVirios Therapeutics Inc
08/08/202415h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
08/08/202415h15GlobeNewswire Inc.Virios Therapeutics Announces Second Quarter 2024 Financial ResultsNASDAQ:VIRIVirios Therapeutics Inc
01/08/202415h41GlobeNewswire Inc.Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024NASDAQ:VIRIVirios Therapeutics Inc
23/07/202415h15GlobeNewswire Inc.Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne CenterNASDAQ:VIRIVirios Therapeutics Inc
20/06/202415h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
12/06/202415h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
22/05/202419h30GlobeNewswire Inc.Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyNASDAQ:VIRIVirios Therapeutics Inc
20/05/202422h05Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:VIRIVirios Therapeutics Inc
20/05/202415h28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
20/05/202402h53GlobeNewswire Inc.Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyNASDAQ:VIRIVirios Therapeutics Inc
17/05/202422h10GlobeNewswire Inc.Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyNASDAQ:VIRIVirios Therapeutics Inc
17/05/202422h01Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:VIRIVirios Therapeutics Inc
10/05/202416h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIRIVirios Therapeutics Inc
09/05/202414h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
09/05/202413h45GlobeNewswire Inc.Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:VIRIVirios Therapeutics Inc
07/05/202423h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
02/05/202415h15GlobeNewswire Inc.Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024NASDAQ:VIRIVirios Therapeutics Inc
26/03/202414h15GlobeNewswire Inc.Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVIDNASDAQ:VIRIVirios Therapeutics Inc
08/03/202423h00Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:VIRIVirios Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VIRI

Kürzlich von Ihnen besucht

ASE
MERKO
Fhl Mermeren
USOTC
FBAK
First National Bank Alaska (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten

BLACK FRIDAY

ADVFN

Seit 25 Jahren im Geschäft 1999-2024

Sparen Sie bis zu 60%* für Euronext Level 2

1 Jahr 40%, 2 Jahre 50% und *3 Jahre 60%

*Über 3 Jahre 1094.04€, jetzt nur noch 437.62€